| 2 0.01 (0.5%) | 03-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.59 | 1-year : | 2.88 |
| Resists | First : | 2.22 | Second : | 2.47 |
| Pivot price | 2.07  |
|||
| Supports | First : | 1.82 | Second : | 1.51 |
| MAs | MA(5) : | 1.95  |
MA(20) : | 2.11 |
| MA(100) : | 4.34 |
MA(250) : | 10.07 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 22 |
D(3) : | 18.9 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 21.6 | Low : | 1.82 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENVB ] has closed above bottom band by 37.8%. Bollinger Bands are 73.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.07 | 2.07 - 2.08 |
| Low: | 1.97 - 1.98 | 1.98 - 1.99 |
| Close: | 1.98 - 2 | 2 - 2.02 |
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Wed, 25 Feb 2026
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent - ChartMill
Thu, 19 Feb 2026
Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals - Sahm
Thu, 19 Feb 2026
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data - Investing News Network
Thu, 29 Jan 2026
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option - Yahoo Finance
Wed, 28 Jan 2026
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Business Wire
Thu, 11 Dec 2025
Enveric Biosciences shareholders approve stock issuance and share increase proposals - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 515460 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 68 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -133.3 % |
| Return on Equity (ttm) | -262.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.17e+007 |
| Qtrly Earnings Growth | 390.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | 2 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.08 |
| Dividend | 0 |
| Forward Dividend | 62030 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|